To optimise patient care and in particular to allow appropriate treatment de-escalation, AJCC 2018 recommends molecular profiling in T1/T2 tumours without lymph node metastases and ER-positive/HER2-negative status. The gene discussed is ERBB2; the disease is neoplasm.